The Journal of Heart and Lung Transplantation
Volume 28, Issue 7 , Page 751 , July 2009

Recovery From Anthracycline Cardiomyopathy–How can it be Explained?

References 

  1. Freilich M, Stub D, Esmore D, et al. Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant. 2009;28:101–103
  2. Simsir SA, Lin SS, Blue LJ, Gockerman JP, Russell SD, Milano CA. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. Ann Thorac Surg. 2005;80:717–719
  3. Casarotto D, Bottio T, Gambino A, Testolin L, Gerosa G. The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation. J Thorac Cardiovasc Surg. 2003;125:417–418
  4. Swartz MF, Fink GW, Carhart RL. Use of a biventricular assist device in the treatment of acute doxorubicin-induced cardiotoxicity. Congest Heart Fail. 2004;10:197–199
  5. Christiansen S, Redmann K, Scheld HH, et al. Adriamycin-induced cardiomyopathy in the canine—an appropriate model for research on partial left ventriculectomy?. J Heart Lung Transplant. 2002;21:783–790
  6. Christiansen S, Perez-Bouza A, Schälte G, Hilgers RD, Autschbach R. Selective left ventricular Adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant. 2008;27:86–92

PII: S1053-2498(09)00223-X

doi: 10.1016/j.healun.2009.04.001

The Journal of Heart and Lung Transplantation
Volume 28, Issue 7 , Page 751 , July 2009

Article Tools